UPDATED May 14, 2024
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
PHM | €34.06 | 7.9% | -2.7% | €600.8m | €49.20 | PE528.4x | E45.0% | 1.9% | Pharmaceuticals & Biotech | ||
SQRL | €1.56 | 4.0% | -36.6% | €138.9m | n/a | PE9.9x | E16.1% | n/a | Media | ||
KOM | €0.80 | 0% | 2.6% | €9.6m | €2.00 | PB0.7x | E98.6% | n/a | Materials | ||
ALM | €9.20 | 3.8% | 7.7% | €1.9b | €11.28 | PS2.1x | E46.7% | 2.1% | Pharmaceuticals & Biotech | ||
CASH | €0.52 | -1.3% | -19.4% | €761.8m | n/a | PE11.5x | E24.2% | 5.1% | Commercial Services | ||
EDR | €6.51 | -0.5% | 27.1% | €808.1m | €9.11 | PS1.3x | E78.3% | n/a | Consumer Services | ||
LLYC | €9.45 | 0.5% | -14.1% | €106.8m | n/a | PE14.6x | E17.0% | 1.4% | Media | ||
ACX | €10.42 | 2.7% | 6.5% | €2.6b | €13.77 | PE17.9x | E27.7% | 6.0% | Materials | ||
ART | €4.80 | 0% | 23.1% | €273.4m | €5.22 | PE22.7x | E28.5% | 2.2% | Capital Goods | ||
GRF | €9.85 | 6.1% | -12.0% | €5.9b | €16.90 | PE112.7x | E28.8% | n/a | Pharmaceuticals & Biotech | ||
ROVI | €84.40 | 1.9% | 98.2% | €4.4b | €85.13 | PE31.7x | E22.3% | 1.3% | Pharmaceuticals & Biotech | ||
PRS | €0.36 | -0.5% | -8.1% | €365.2m | n/a | PE-20.1x | E81.7% | n/a | Media | ||
APPS | €12.70 | 0.2% | 43.3% | €1.6b | €11.71 | PE62.7x | E32.5% | 1.3% | Commercial Services | ||
IDR | €20.00 | 1.3% | 68.6% | €3.5b | €22.13 | PE15.6x | E12.4% | 1.3% | Software | ||
CLNX | €33.83 | 3.0% | -11.5% | €23.9b | €42.40 | PS6.2x | E69.1% | 0.2% | Telecom |